BioMarin Pharmaceutical (BMRN) late Wednesday reported Q4 non-GAAP earnings of $0.92 per diluted share, compared with $0.49 a year earlier.
Analysts polled by FactSet expected $0.74.
Revenue for the quarter ended Dec. 31 was $747.3 million, compared with $646.2 million a year earlier.
Analysts polled by FactSet expected $712.3 million.
For 2025, the company is projecting non-GAAP EPS of $4.20 to $4.40 on revenue of $3.1 billion to $3.2 billion. Analysts polled by FactSet are looking for $4.15 and $3.10 billion, respectively.
BioMarin shares recently were up 8.2% in Wednesday's after-hours session.
Price: 71.00, Change: +5.39, Percent Change: +8.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.